Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advarra, Inc.

Neither a doctor nor a teaching hospital

Research payments

$408,471

472 payments

Through program year 2025, Advarra, Inc. is reported as receiving $408,471 in research payments, across 472 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $161,854 234
2024 Research $38,020 30
2023 Research $119,924 108
2022 Research $9,565 8
2021 Research $34,461 27
2020 Research $14,735 14
2019 Research $29,912 51

Breakdown

Who paid Research payments · program years 2019–2025
  1. Idorsia Pharmaceuticals US Inc $204,299 242 payments
  2. EMD Serono, Inc. $53,835 65 payments
  3. Novocure Inc. $52,230 33 payments
  4. Zimmer Biomet Holdings, Inc. $29,901 30 payments
  5. Topcon Medical Systems, Inc. $27,140 21 payments
  6. Celgene Corporation $12,525 36 payments
  7. Dompe Farmaceutici S.p.A. $9,355 21 payments
  8. Neurocrine Biosciences, Inc. $7,804 11 payments
  9. Mercator MedSystems, Inc. $3,810 2 payments
  10. PENTAX of America, Inc. $3,785 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder $69,920 88 payments
  2. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Polysomnography, Dose-Finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-Dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder $68,108 54 payments
  3. Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) $53,490 64 payments
  4. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 2-Way Cross-Over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia $38,736 46 payments
  5. EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. $31,590 17 payments
  6. Neco2022-001 Protocol $27,140 21 payments
  7. A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy $24,665 45 payments
  8. EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma $11,070 8 payments
  9. EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma $9,570 8 payments
  10. Celgene - Connect MDSAML $7,950 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record